Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%
Market cap
$1.2B
P/E
16.4×
Fwd P/E
21.4×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

8 8 8 8
ROE
3.85% 10.98% 13.57% 22.75%
ROA
1.03% 3.22% 4.24% 7.89%
ROIC
5.41% 7.16% 7.64% 7.34%
Return on Tangible Assets
5.34% 16.92% 23.15% 43.36%
Average Days of Receivables
84.42 82.44 76.33 86.82
Free Cash Flow per Share
0.80 1.08 1.50 1.39
Free Cash Flow
53.47 72.11 100.63 94.29
Capital Expenditures
(2.56) (2.56) (2.31) (2.59)
Other line items
Cash ROIC
9.35% 12.57% 18.56% 16.98%
Accounts Receivable Turnover
4.47 4.44 4.83 4.30
Accounts Payable Turnover
8.36 10.40 8.34 8.21
Inventory Turnover
1.95 2.06 2.04 2.07
Average Days of Payables
53.50 22.17 48.65 40.41
Days of Inventory on Hand
193.29 166.82 168.28 159.70
Tax Rate
(0.19) 0.06 0.03 0.59
Research and Development Expense of Revenue
2.20% 2.13% 2.01% 1.99%
Selling, General and Administrative Expense of Revenue
56.43% 55.28% 55.33% 55.42%
Share Based Compensation of Revenue
2.00% 2.23% 2.35% 2.56%
Interest Coverage
1.40 2.04 2.47 2.93
Operating CF/Net income
7.38 3.28 3.61 1.78
Depreciation/Fixed assets
2.08 2.15 2.18 2.20
Capex/Depreciation
(0.05) (0.05) (0.05) (0.06)
Revenue per Share
8.42 8.53 8.56 8.57
Operating CF per Share
0.84 1.12 1.53 1.43
Capex per Share
(0.04) (0.04) (0.03) (0.04)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates